PCG Molecular Testing Menu
®
Detecting Cancer and Infectious Disease Before it Becomes Life-Threatening
PCG molecular strives to change the way we practice health care. That means keeping patients healthy by screening them responsibly and regularly. Our company aspires to move patients and practitioners away from reactive care and into a proactive mindset that saves lives and improves the outcomes for many more. When our doctors and lab technicians look at developing new and innovative molecular screens we look at the following underlying principles: Will it provide the medical community and their patients with a preventive screening test that does not exist for certain cancers and diseases? Will it catch disease before it has become stage three or four cancer that is irreversible and devastating? Will it help to prevent the spread of viruses or aid in their treatment if diagnosed? Will it identify those who are at higher risk for developing a disease or a cancer so they can be watched more closely by their practitioners? And finally, is it less invasive or more effective than current test?
​
Neoplastic and Anal Infectious Disease Panel
Respiratory Infectious Disease Panel

Respiratory One PAP
molecular respiratory panel
SARS-CoV-2 is a top concern for patients and clinicians, but several respiratory pathogens can cause nearly indistinguishable symptoms. The FDA De Novo authorized PCG Molecular RP2.1 Panel® is a frontline test to help clinicians quickly diagnose respiratory infections, including COVID-19, influenza, RSV, and many others.
®
Gastrointestinal (GI) Panel
G.I One PAP
molecular gastroenteritis panel
®
The G.I One PAP® tests stool specimens for common pathogens associated with gastroenteritis. Quickly identifying the correct pathogen can ensure appropriate treatment, improve patient management, and help detect infectious gastroenteritis which can lead to severe illness or death.

